Cytokine and growth factor involvement in schizophrenia - Support for the developmental model

Molecular Psychiatry

Volumn 5, Issue 6, 2000, Pages 594-603

  Nawa, H ^a   Takahashi, M ^b   Patterson, P H ^c  

^a NIIGATA UNIVERSITY   (Japan)

^b National Saigata Medical Center   (Japan)

^c CALIFORNIA INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

BDNF; Cytokine; Development; Dysplasia; GABA; Glutamate receptor; Interferon; Interleukin; Limbic system; Neuro transmitter; Neurotrophin; Synaptic plasticity

Indexed keywords

4 AMINOBUTYRIC ACID; BRAIN DERIVED NEUROTROPHIC FACTOR; CYTOKINE; GLUTAMATE RECEPTOR; GROWTH FACTOR; INTERFERON; NEUROTROPHIC FACTOR;

ARTICLE; CYTOKINE PRODUCTION; HUMAN; MENTAL DISEASE; NERVE CELL DIFFERENTIATION; NERVE CELL PLASTICITY; PRIORITY JOURNAL; SCHIZOPHRENIA; SYNAPTIC TRANSMISSION;

EID: 0033659799     PISSN: 13594184     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.mp.4000730     Document Type: Article

References (144)

1. A turning point in schizophrenia genetics
2. Critical review of recent adoption, twin, and family studies of schizophrenia: Behavioral genetics perspectives
3. Effects of family history and place and season of birth on the risk of schizophrenia
4. Perinatal risk factors and schizophrenia: Selective review and methodological concerns
5. Schizophrenia after prenatal exposure to 1957 A2 influenza epidemic
6. Schizophrenia after prenatal famine. Further evidence
7. The association between season of birth and the risk for schizophrenia
8. Implication of normal brain development for the pathogenesis of schizophrenia
9. Schizophrenia: Developmental neuroscience and pathobiology
10. Recent advances in the neuropathology of schizophrenia
11. From neuropathology to neurodevelopment
12. Psychoneuroimmunology and the cytokine action in the CNS: Implications for psychiatric disorders
13. Coordinated host defense through an integration of the neural, immune and haemopoietic systems
14. Neuropsychiatric aspects of cytokines research: An overview
15. Altered distribution of nicotinamide-adenine dinucleotide phosphate-diaphorase cells in frontal lobe of schizophrenics implies disturbances of cortical development
16. Distorted distribution of nicotinamide-adenine dinucleotide phosphate-diaphorase neurons in temporal lobe of schizophrenics implies anomalocortical development
17. Neurobiological investigations in cingulate cortex of schizophrenic brain
18. Cerebral structural pathology in schizophrenia: Evidence for a selective prefrontal cortical defect
19. Schizophrenia and the hippocampus: The embryological hypothesis extended
20. Circumscribed malformation and nerve cell alterations in the entorhinal cortex of schizophrenics. Pathogenetic and clinical aspects
21. Schizophrenia: The cellular biology of a functional psychosis
22. The neuropathology of schizophrenia. A critical review of the data and their interpretation
23. An integrated view of pathophysiological models of schizophrenia
24. Cell biology of the hippocampal formation in schizophrenia
25. Schizophrenia, the heteromodal association neocortex and development: Potential for a neurogenetic approach
26. The genetics of schizophrenia is the genetics of neurodevelopment
27. Altered synaptophysin expression as a marker of synaptic pathology in schizophrenia
28. Decreased synaptophysin in the medial temporal lobe in schizophrenia demonstrated using immunoautoradiography
29. Reduction of synaptophysin immunoreactivity in the prefrontal cortex of subjects with schizophrenia. Regional and diagnostic specificity
30. Levels of the growth-associated protein GAP-43 are selectively increased in association cortices in schizophrenia
31. Increased concentrations of presynaptic proteins in the cingulate cortex of subjects with schizophrenia
32. Significant reductions in synapsin but not synaptophysin specific activity in the brains of some schizophrenics
33. Abnormal reinnervation as a basis for schizophrenia: A hypothesis
34. Increased density of microtubule associated protein 2-immunoreactive neurons in the prefrontal white matter of schizophrenic subjects
35. Abnornial expression of two microtubule-associated proteins (MAP2 and MAP5) in specific subfields of the hippocampal formation in schizophrenia
36. Decreased expression of the embryonic form of the neural cell adhesion molecule in schizophrenic brains
37. Cingulate cortex synaptic terminal proteins and neural cell adhesion molecule in schizophrenia
38. Hippocampal long-term potentiation and neural cell adhesion molecules L1 and NCAM
39. The relationship between adhesion molecules and neuronal plasticity
40. Transmitter dysfunction during the process of schizophrenia
41. Regional brain concentrations of neuropeptides in Huntington's chorea and schizophrenia
42. Reduced cholecystokinin-like and somatostatin-like immunoreactivity in limbic lobe is associated with negative m symptoms in schizophrenia
43. Decreased expression of mRNAs encoding non-NMDA glutamate receptors GluR1 and GluR2 in medial temporal lobe neurons in schizophrenia
44. GluR2 glutamate receptor subunit flip and flop isoforms are decreased m the hippocampal formation in schizophrenia: A reverse transcriptase polymerase chain reaction (RT-PCR) study
45. Decreased hippocampal expression of a glutamate receptor gone in schizophrenia
46. Distribution of kainate receptar subunit mRNAs in human hippocampus, neocortex and cerebellum, and bilateral reduction of hippocampal GluR6 and KA2 transcripts in schizophrenia
47. Immunoautoradiographic evidence for a loss of alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate-preferring non N-methyl-D-aspartate glutamate receptors within the medial temporal lobe in schizophrenia
48. Increased GABAA receptor binding in superficial layers of cingulate cortex in schizophrenics
49. Up-regulation of GABAA receptor binding on neurons of the prefrontal cortex in schizophrenic subjects
50. 3H]muscimol binding sites increased in autopsied brains of chronic schizophrenics
51. Expression of NMDAR1, GluR1, GluR7, and KA1 glutamate receptor mRNAs is decreased in frontal cortex of 'neuroleptic-free' schizophrenics: Evidence on reversible up-regulation by typical neuroleptics
52. Regulation of neuropeptides in adult rat forebrain by the neurotrophins BDNF and NGF
53. Brain-derived naurotrophic factor promotes differentiation of striatal GABAergic neurons
54. Regulation of neuropeptide expression in cultured cerebral cortical neurons by brain-derived neurotrophic factor
55. Intraventricular administration of BDNF increases neuropeptide expression in newborn rat brain
56. BDNF protein measured by a novel enzyme immunoassay in normal brain and after seizure: Partial disagreement with mRNA levels
57. Brain-derived neurotrophic factor regulates the expression of AMPA receptor proteins in neocortical neurons
58. Growth factor-mediated fyn signaling regulates AMPA receptor expression in rodent neocortical neurons
59. Mutual regulation between the intercellular messengers nitric oxide and brain-derived neurotrophic factor in rodent neocortical neurons
60. Nerve growth factor (NGF) prevents the shift in ocular dominance distribution of visual cortical neurons in monocularly deprived rats
61. Inhibition of ocular dominance column formation by infusion of NT-4/5 or BDNF
62. Neurotrophins regulate dendritic growth in developing visual cortex
63. RAPID and opposite effects of BDNF and NGF on the functional organization of the adult cortex in vivo
64. Maldistribution of interstitial neurons in prefrontal white matter of the brains of schizophrenic patients
65. Transient cells of the developing mammalian telencephalon are peptide-immunoreactive neurons
66. Gene expression for glutamic acid decarboxylase is reduced without loss of neurons in prefrontal cortex of schizophrenics
67. The phenotypic characteristics of heterozygous reeler mouse
68. BDNF regulates reelin expression and Cajal-Retzius cell development in the cerebral cortex
69. BDNF regulates reelin expression and Cajal-Retzius cell development in the cerebral cortex
70. A decrease of reelin expression as a putative vulnerability factor in schizophrenia
71. Brain-derived neurotrophic factor gene schizophrenia in Japanese subjects
72. Temperature gradient gel electrophoresis analysis of the beta-NGF gene in schizophrenia
73. Neurotrophin-3 gene polymorphism associated with schizophrenia
74. Association between a null mutation in the human ciliary neurotrophic factor (CNTF) gene and increased incidence of psychiatric diseases?
75. Cytokines in affective disorders and schizophrenia: New clinical and genetic findings
76. Abnormal expression of brain-derived neurotrophic factor and its receptor in the corticolimbic system of schizophrenic patients
77. Reduced tyrosine kinase receptor C mRNA levels in the frontal cortex of patients with schizophrenia
78. Large individual variations in BDNF content in human brain and serum
79. Patients with temporal lobe epilepsy show an increase in brain-derived neurotrophic factor protein and its correlation with neuropeptide Y
80. Effects of stress on neurotrophic factor expression in the rat brain
81. Heritability of BDNF alleles and their effect on brain morphology in schizophrenia
82. No evidence for association between CNTF null mutant allele and schizophrenia
83. An association study of a neurotrophin-3 (NT-3) gene polymorphism with schizophrenia
84. Polymorphisms of the interleukin-1 gene complex in schizophrenia
85. Neuronal differentiation factors/cytokines and synaptic plasticity
86. Pathways and mechanisms for cytokine signalling of the central nervous system
87. Synaptic modulation by neurotrophic factors
88. Neurotrophin regulation of synaptic transmission
89. Cytokine and growth factor involvement in long term potentiation
90. Cytokine gene expression within the central nervous system
91. The role of cytokines and growth factors in seizure and its sequelae
92. Hepatitis C and depression
93. Pattern of neurobehavioral deficits associated with interferon alfa therapy for leukemia
94. The role of inflammatory mediators in the biology of major depression: Central nervous system cytokines modulate the biological substrate of depressive symptoms, regulate stress-responsive systems, and contribute to neurotoxicity and neuroprotection
95. The neuropsychiatric effects of treatment with interleukin-2 and lymphokine-activated killer cells
96. HIV-1-infection in the CNS. A pathogenesis of some neurological syndromes in the light of recent investigations
97. Systemic interleukin-1 beta decreases brain-derived neurotrophic factor messenger RNA expression in the rat hippocampal formation
98. The glutamate receptor-mediated regulation of brain-derived neurotrophic factor production by cytokines in central nervous system
99. Interleukin-1 regulates synthesis of nerve growth factor in non-neuronal cells of rat sciatic nerve
100. Inflammatory signals induce neurotrophin expression in human microglial cells
101. Defective corticogenesis and reduction in Reelin immunoreactivity in cortex and hippocampus of prenatally infected neonatal mice
102. Dopamine in schizophrenia: A review and reconceptualization
103. Excitatory amino acids: Implications for psychiatric disorders research
104. BDNF has opposite effects on the quantal amplitude of pyramidal neuron and interneuron excitatory synapses
105. Overlapping and distinct actions of the neurotrophins BDNF, NT-3, and NT-4/5 on cultured dopaminergic and GABAergic neurons of the ventral mesencephalon
106. Brain-derived neurotrophic factor augments rotational behavior and nigrostriatal dopamine turnover in vivo
107. Brain-derived neurotrophic factor works coordinately with partner molecules to initiate tyrosine hydroxylase expression in striatal neurons
108. Neurotransmitter regulation of neuronal outgrowth, plasticity and survival
109. Interactions between entorhinal axons and target hippocampal neurons: A role for glutamate in the development of hippocampal circuitry
110. Physiological and pathophysiological roles of excitatory amino acids during central nervous system development
111. D1/D5 dopamine receptor activation increases the magnitude of early long-term potentiation at CA1 hippocampal synapses
112. Site-specific and sensory neuron-dependent increases in postsynaptic glutamate sensitivity accompany serotonin-induced long-term facilitation at Aplysia sensorimotor synapses
113. Monozygotic twins discordant for schizophrenia are discordant for N-CAM and L1 in CSF
114. Alterations in hippocampal non-phosphorylated MAP2 protein expression in schizophrenia
115. Cholecystokinin messenger RNA deficit in frontal and temporal cerebral cortex in schizophrenia
116. Glutamate receptor subtype expression in human postmortem brain tissue from schizophrenics and alcohol abusers
117. Selective alterations in gene expression for NMDA receptor subunits in prefrontal cortex of schizophrenics
118. Altered ratios of alternatively spliced long and short gamma2 subunit mRNAs of the gamma-amino butyrate type A receptor in prefrontal cortex of schizophrenics
119. Dopamine D1 receptor, D2 receptor, proenkephalin A and substance P gene expression in the caudate nucleus of control and schizophrenic tissue: A quantitative cellular in situ hybridisation study
120. Selective loss of dopamine D3-type receptor mRNA expression in parietal and motor cortices of patients with chronic schizophrenia
121. Enhanced cleavage of an atypical intron of dopamine D3-receptor pre-mRNA in chronic schizophrenia
122. No difference in the expression of the D4 gene in post-mortem frontal cortex from controls and schizophrenics
123. The relative abundance of dopamine D4 receptor mRNA in post mortem brains of schizophrenics and controls
124. Elevation of D4 dopamine receptor mRNA in postmortem schizophrenic brain
125. 5-HT1A and 5-HT2A receptor mRNAs and binding site densities are differentially altered in schizophrenia
126. Nerve growth factor increases choline acetyltransferase but not survival or fiber outgrowth of cultured fetal septal cholinergic neurons
127. Brain-derived neurotrophic factor promotes the differentiation of various hippocampal nonpyramidal neurons, including Cajal-Retzius cells, in organotypic slice cultures
128. Neurotrophins and basic fibroblast growth factor induce the differentiation of calbindin-containing neurons in the cerebral cortex
129. Mutual regulation between the intercellular messengers nitric oxide and brain-derived neurotrophic factor in rodent neocortical neurons
130. Brain-derived neurotrophic factor regulates the expression of AMPA receptor proteins in neocortical neurons
131. Induction of dopaminergic neurotransmitter phenotype in rat embryonic cerebrocortex by the synergistic action of neurotrophins and dopamine
132. Brain-derived neurotrophic factor increases the stimulation-evoked release of glutamate and the levels of exocytosis-associated proteins in cultured cortical neurons from embryonic rats
133. Regulation of the transmitter phenotype of rostral and caudal groups of cultured serotonergic raphe neurons
134. Neuregulin-beta induces expression of an NMDA-receptor subunit
135. 2+ responses to AMPA and NMDA in hippocampal neurons
136. Glial cell line-derived neurotrophic factor induces the dopaminergic and cholinergic phenotype and increases locomotor activity in aged Fischer 344 rats
137. Interleukin-1 beta stimulates somatostatin biosynthesis in primary cultures of fetal rat brain
138. Differentiation of mesencephalic progenitor cells into dopaminergic neurons by cytokines
139. Interleukin 3 as atrophic factor for central cholinergic neurons in vitro and in vivo
140. Interleukin-6 improves the survival of mesencephalic catecholaminergic and septal cholinergic neurons from postnatal, two-week-old rats in cultures
141. CNTF induces raphe neuronal precursors to switch from a serotonergic to a cholinergic phenotype in vitro
142. Role of interleukin-6 and soluble IL-6 receptor in region-specific induction of astrocytic differentiation and neurotrophin expression
143. Leukemia inhibitory factor augments neurotrophin expression and corticospinal axon growth after adult CNS injury
144. Interleukin 1 expression is inducible by nerve growth factor in PC12 pheochromocytoma cells